Preview Mode Links will not work in preview mode

I am Dr. Todd Brandt. I am a urologist. 

These are words I couldn't have imagined myself saying as I was growing up thinking about medicine as a career. 

And I have been asked many, many times why I went into urology as a medical specialty. In this podcast I attempt to explain how I got here. Why did I choose urology as a specialty? Why do I like it? Why, if you are someone with a urinary tract, should you care? Get it? Why Urology.

This podcast is a personal experiment in medical audio content. I make the obvious disclaimer that this is not medical advice. You should be going to your own physician for that.

These episodes are meant to educate, entertain, inspire or inform you in some way with urology as the launching point for each episode. Each episode is varied in format and length as I have experimented with content. 

Listen, follow, share, rate, review, know what to do.

If you have kidney stones, or prostate cancer, or another urologic health concern this podcast may help you.

If you have a loved one with any urologic health concern this podcast may help you. 

If you are someone who has asked, "How does my bladder do it's thing?", this podcast may help you.

If you make urine, or even if you don't, this podcast may help you.

Thank you for listening to this podcast. I do appreciated any feedback I get so please reach out to me at the link provided on this website. 

Be well,

Dr. Todd Brandt

Aug 28, 2016

Men with prostate cancer are living longer, but many survive with a greater burden of treatment. More than one-third of the nearly three million prostate cancer survivors in the United States currently receive androgen deprivation therapy (ADT). ADT improves the clinical outcomes for men with prostate cancer in...

Aug 19, 2016

Dr. Charles Huggins groundbreaking research on prostate cancer from the 1940s about the androgen sensitivity of prostate cancer.

Aug 1, 2016

Dr. Todd Brandt discusses PSA screening in African-American men , highlighting the need for greater screening within that population given the higher incidence of prostate cancer and the greater risk of more aggressive disease.

Link to New York Times Op-Ed piece: